


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



**TRANSMITTAL
FORM**

 TRANSMITTAL FORM <small>U.S. TRADEMARK OFFICE To be used for all correspondence after initial filing</small>	Application Number	10/533,764	
	Filing Date	May 4, 2005	
	First Named Inventor	William Brown	
	Art Unit	To Be Determined	
	Examiner Name	To Be Determined	
Total Number of Pages in This Submission		Attorney Docket Number	ASZN0036-100 (100884-1P US)

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input checked="" type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	Statement under 37 CFR 3.73(b) with copy of Assignment executed by ALL inventors to AstraZeneca AB (3 pp. total)
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application	Remarks	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm	Cozen O'Connor		
Signature			
Printed Name	Paul K. Legaard, Ph.D.		
Date	30 November 2009	Reg. No.	38,534

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Signature			
Typed or printed name	Paul K. Legaard, Ph.D., Registration No. 38,534	Date	30 November 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/81 (11-04)

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

POWER OF ATTORNEY
and
CORRESPONDENCE ADDRESS
INDICATION FORM

Application Number	10/533,764
Filing Date	May 4, 2005
First Named Inventor	William Brown
Title	4(PHENYL-PIPERAZINYL-METHYL) BENZAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PAIN OR GASTROINTESTINAL DISORDERS
Art Unit	To Be Determined
Examiner Name	To Be Determined
Attorney Docket No.	ASZN0036-100 (100884-1P US)

I hereby revoke all previous powers of attorney given in the above-identified application.

I hereby appoint:

Practitioners associated with the Customer Number:

52286

OR

Practitioner(s) named below:

Name	Registration Number

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please recognize or change the correspondence address for the above-identified application to:

The address associated with the above-mentioned Customer Number

OR

The address associated with Customer Number:

OR

<input type="checkbox"/> Firm or Individual Name			
Address			
City	State	ZIP	
Country			
Telephone	Fax		

I am the:

Applicant/Inventor.
 Assignee of record of the entire interest. See 37 CFR 3.71.

Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

SIGNATURE of Applicant or Assignee of Record

Signature		Date	3 October 2005
Name	Anna-Lena Rosendahl	Telephone	
Title and Company	Director IP Services, AstraZeneca AB		

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

*Total of forms are submitted.

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



DOCKET NO.: ASZN0036-100 (100884-1P US)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: **Brown and Griffin**

Serial No.: **10/533,764**

Art Unit: **To Be Determined**

Filing Date: **May 4, 2005**

Examiner: **To Be Determined**

For: **4(PHENYL-PIPERAZINYLMETHYL) BENZAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PAIN OR GASTROINTESTINAL DISORDERS**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

STATEMENT UNDER 37 CFR 3.73(b)

Applicant or Patent Owner, **ASTRAZENECA AB**, a company created and existing under the laws of **Sweden**, of Application No. **10/533,764** filed on **May 4, 2005** and entitled **4(PHENYL-PIPERAZINYLMETHYL) BENZAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PAIN OR GASTROINTESTINAL DISORDERS**, states that it is:

the assignee of the entire right, title, and interest; or
 an assignee of less than the entire right, title, and interest.

The extent (by, percentage) of its ownership interest is **100%** in the patent application/patent identified above by virtue of either:


A copy of the assignment from the inventor(s) of the patent application identified above is enclosed herewith.

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Respectfully submitted,

AstraZeneca AB

Date: 3 October 2005

By: 

Name: Anna-Lena Rosendahl
Title: Director IP Services

ATTORNEY DOCKET NO.:
AstraZeneca Ref.: 100884-1P US

ASSIGNMENT

Now, therefore, for good and valuable consideration, receipt and sufficiency of which is hereby acknowledged, I/we

William BROWN and Andrew GRIFFIN both of AstraZeneca R&D Montreal, 7171 Frederick-Banting, St. Laurent, Montreal, Quebec H4S 1Z9, Canada;

hereafter referred to as ASSIGNOR (S),

Hereby sell(s), assign(s) and transfer(s) to ASSIGNEE **AstraZeneca AB**, a company created and existing under the laws of Sweden, having its Head Office at SE-151 85 Södertälje, Sweden, and the successors, assigns and legal representatives of the ASSIGNEE, the entire right, title and interest for the United States and its territorial possessions, and in all foreign countries, in and to the inventions and any and all improvements thereon which are the subject of an application entitled:

4(PHENYL-PIPERAZINYL-METHYL) BENZAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PAIN OR GASTROINTESTINAL DISORDERS

And which is disclosed in:

- (a) U.S. patent application executed on even date herewith;
- (b) U.S. patent application executed on _____;
- (c) U.S. application no. _____ filed on _____;
- (d) International application no. PCT/SE2003/001706 filed on 5 November 2003.

And in and to the above application and any legal equivalent thereof in a foreign country, including the right to claim priority, and in and to any division, continuation or continuation-in-part, renewal or substitute thereof, and in and to all resulting Letters Patents or any reissue or reexamination thereof, to have and to hold the same to the full end of the term or terms for which any and all of said Letters Patent may be granted;

ASSGNOR(S) authorize(s) and request(s) the issuing authority to issue any and all patents on said application or applications to said ASSIGNEE or its successors and assigns;

ASSIGNOR(S) hereby covenant(s) that ASSIGNOR(S) has/have the full power to make this assignment, and that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment; and

Without further payment or compensation by the ASSIGNEE or its successors and assigns, ASSIGNOR(S) further covenant(s) and agree(s) to communicate to said ASSIGNEE or its representatives, agents, its successors or assigns, any facts relating to said invention or inventions including evidence for purposes of interference or other administrative or legal proceedings whenever requested; to testify in any interference, legal or administrative proceedings, whenever requested; to execute and deliver, on request, all lawful papers required to make any of the foregoing provisions effective; and to do everything possible to aid said ASSIGNEE, its successors or assigns and nominees to secure, obtain and enforce proper patent protection for said invention or inventions in this or any foreign country.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.

IN WITNESS WHEREOF, I have hereunto set my hand and seal on the date below written.

.....
William BROWN

Signature of Assignor

WITNESSED BY:

.....
Andrea Bower Karsz

Signature of Witness

Name of Witness

(Type or print clearly)

.....
Carole Bower Karsz

.....
April 19/2005

Date of Assignor's Signature

.....
Marie Le Francois

Signature of Witness

Name of Witness

(Type or print clearly)

.....
MARIÉ LE FRANCOIS

IN WITNESS WHEREOF, I have hereunto set my hand and seal on the date below written.

.....
Andrew GRIFFIN

Signature of Assignor

WITNESSED BY:

.....
Andrea Bower Karsz

Signature of Witness

Name of Witness

(Type or print clearly)

.....
Carole Bower Karsz

.....
19th April 2005

Date of Assignor's Signature

.....
Marie Le Francois

Signature of Witness

Name of Witness

(Type or print clearly)

.....
MARIÉ LE FRANCOIS

Additional signature pages attached: Yes No